Clinical Trials Development Resource for Hematologic Disorders (U24)

血液疾病临床试验开发资源 (U24)

• 批准号: 8693647
• 负责人: Donald Brambilla
• 金额: $ 70.77万
• 依托单位: RESEARCH TRIANGLE INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8693647
• 关键词: Address; Adverse event; Bioethics Consultants; Case Report Form; Clinical Investigator; Clinical Research; Clinical Trials; Clinical Trials Design; Commit; Conduct Clinical Trials; Consent Forms; Critiques; Data; Data Quality; Development; Disease; Drug Formulations; Educational process of instructing; Enrollment; Ethics; Face; Future; Hematological Disease; Hematologist; Hematology; Hemophilia A; Human Resources; Individual; Institutional Review Boards; Instruction; International; Knowledge; Lead; Leadership; Manuals; Measurement; Mentors; Monitor; Online Systems; Patients; Pharmaceutical Preparations; Phase; Placebos; Positioning Attribute; Principal Investigator; Procedures; Production; Protocols documentation; Randomized; Regulatory Affairs; Reporting; Research; Research Design; Research Personnel; Resource Development; Resources; Role; Sample Size; Schedule; Scheme; Sickle Cell Anemia; Site; Specialist; Specific qualifier value; System; Testing; Therapy Clinical Trials; Training; Work; abstracting; base; data management; design; experience; implementation trial; improved; member; operation; programs; quality assurance; skills; sound; standard of care; success; tool; treatment effect; treatment site; willingness

DESCRIPTION (provided by applicant): RTI International is submitting this application for the Clinical Trials Development Resource for Hematologic Disorders (U24), RFA-HL-12-016. The Resource will support the development of clinical trials by investigators who have ideas for new treatments of blood disorders but lack access to the resources needed to design trials to test these ideas. The RTI Resource team includes highly experienced individuals with diverse backgrounds that cover all aspects of multicenter clinical trials. Our biostatisticians have collaborated extensively with clinical investigators on trial design, monitoring, and analysis, including trials in hematological diseases (sickle cell disease, hemophilia and TTP). Clinical study managers will advise on the practical aspects of trial implementation (recruitment of study sites and subjects, and development of manuals of operations and other study materials). The team includes expert programmers to advise on data entry and data management systems, regulatory specialists with experience interacting with FDA and other regulatory agencies, and bioethicists to advise on ethical conduct of clinical trials. Our team also includes several hematology consultants experienced in designing clinical trials for a wide range of blood disorders. Finally, our team includes groups with considerable experience offering formal training on trial design and management. Drawing on this broad-based expertise, the RTI Resource will accomplish two broad Aims. First, advice from the Resource will provide the R34/U34 investigators with the tools and knowledge that they need to develop high-quality, effective proposals at the end of the trial planning phase. Also, that advice will lead to development by the R34/U34 investigators of feasible, scientifically sound, well-designed protocols that can be implemented efficiently through an R01/U01 mechanism. We will offer training and mentoring to improve the design skills of the investigators so as to improve future research studies beyond the term of the Resource. Scientific leadership will be provided Dr. Donald Brambilia as the Resource Principal Investigator who has over 25 years of experience as a statistician in leadership of clinical trials including 20 years in hematological studies working with many of the leading research hematologists in the nation. Dr. Nigel Key is our lead hematology consultant cooperating with 5 other hematologists to support the U34/R34 investigators. We also include personnel with experience in all aspects for clinical trials design, development, implementation and operations. (End of Abstract)

描述（由申请人提供）：RTI International正在提交血液病临床试验开发资源（U24）RFA-HL-12-016的申请。该资源将支持研究人员开发临床试验，这些研究人员有血液疾病新疗法的想法，但无法获得设计试验以测试这些想法所需的资源。RTI的资源团队包括经验丰富的个人，具有不同的背景，涵盖了多中心临床试验的各个方面。我们的生物统计学家与临床研究者在试验设计、监测和分析方面进行了广泛的合作，包括血液病（镰状细胞病、血友病和TTP）试验。临床研究经理将就试验实施的实际方面提供建议（招募研究中心和受试者，以及制定操作手册和其他研究材料）。该团队包括为数据输入和数据管理系统提供建议的专家程序员，具有与FDA和其他监管机构互动经验的监管专家，以及为临床试验伦理行为提供建议的生物伦理学家。我们的团队还包括几位在设计各种血液疾病临床试验方面经验丰富的血液学顾问。最后，我们的团队包括具有丰富经验的小组，提供有关试验设计和管理的正式培训。利用这一基础广泛的专业知识，RTI资源将实现两大目标。首先，来自资源的建议将为R34/U34研究者提供他们在试验计划阶段结束时制定高质量、有效提案所需的工具和知识。此外，这些建议将导致R34/U34调查人员制定可行的、科学合理的、精心设计的协议，这些协议可以通过R 01/U 01机制有效地执行。我们将提供培训和指导，以提高研究人员的设计技能，从而提高未来的研究超出资源的期限。Donald Brambilia博士将作为资源主要研究者提供科学领导，他在临床试验领导方面拥有超过25年的统计学家经验，包括20年的血液学研究经验，与全国许多领先的研究血液学家合作。奈杰尔Key博士是我们的首席血液学顾问，与其他5名血液学家合作，为U34/R34研究者提供支持。我们还包括在临床试验设计的各个方面都有经验的人员， 开发、实施和运营。(End摘要）